Low ERCC1 expression is a good predictive marker in lung adenocarcinoma patients receiving chemotherapy based on platinum in all TNM stages - a single-center study
Abstract Background High ERCC1 expression is thought to be related with resistance to chemotherapy based on platinum. The aim of this study was to present our institutional observations regarding to the association of ERCC1 and overall survival (OS) of the lung adenocarcinoma patients who received c...
Saved in:
Main Authors: | Marina Piljić Burazer (Author), Suzana Mladinov (Author), Antonela Matana (Author), Sendi Kuret (Author), Joško Bezić (Author), Merica Glavina Durdov (Author) |
---|---|
Format: | Book |
Published: |
BMC,
2019-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Trial of a Novel Oral Cannabinoid Formulation in Patients with Hypertension: A Double-Blind, Placebo-Controlled Pharmacogenetic Study
by: Ana Batinic, et al.
Published: (2023) -
<i>ERCC1</i> and <i>ERCC2</i> Polymorphisms Predict the Efficacy and Toxicity of Platinum-Based Chemotherapy in Small Cell Lung Cancer
by: Andrés Barba, et al.
Published: (2024) -
Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis
by: Ning Tang, et al.
Published: (2017) -
Factors That Determine Completion Rates of Biomedical Students in a PhD Programme
by: Benjamin Benzon, et al.
Published: (2020) -
ERCC1 rs11615 polymorphism and chemosensitivity to platinum drugs in patients with ovarian cancer: a systematic review and meta-analysis
by: Yuqiang Zhang, et al.
Published: (2021)